Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. Fundamental Analysis
Chugai Pharmaceutical Co., Ltd. (CHGCY) shows moderate financial fundamentals with a PE ratio of 36.64, profit margin of 34.50%, and ROE of 23.22%. The company generates $1319.0B in annual revenue with moderate year-over-year growth of 5.33%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 85.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze CHGCY's fundamental strength across five key dimensions:
Efficiency Score
ExcellentCHGCY demonstrates superior asset utilization.
Valuation Score
ModerateCHGCY shows balanced valuation metrics.
Growth Score
ExcellentCHGCY delivers strong and consistent growth momentum.
Financial Health Score
ExcellentCHGCY maintains a strong and stable balance sheet.
Profitability Score
ExcellentCHGCY achieves industry-leading margins.
Key Financial Metrics
Is CHGCY Expensive or Cheap?
P/E Ratio
CHGCY trades at 36.64 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CHGCY's PEG of 0.02 indicates potential undervaluation.
Price to Book
The market values Chugai Pharmaceutical Co., Ltd. at 8.22 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 25.83 times EBITDA. This signals the market has high growth expectations.
How Well Does CHGCY Make Money?
Net Profit Margin
For every $100 in sales, Chugai Pharmaceutical Co., Ltd. keeps $34.50 as profit after all expenses.
Operating Margin
Core operations generate 46.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $23.22 in profit for every $100 of shareholder equity.
ROA
Chugai Pharmaceutical Co., Ltd. generates $18.42 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Chugai Pharmaceutical Co., Ltd. generates strong operating cash flow of $396.40B, reflecting robust business health.
Free Cash Flow
Chugai Pharmaceutical Co., Ltd. generates strong free cash flow of $319.04B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $96.93 in free cash annually.
FCF Yield
CHGCY converts 1.88% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
36.64
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.22
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.64
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.23
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.23
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
0.30
vs 25 benchmark
How CHGCY Stacks Against Its Sector Peers
| Metric | CHGCY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 36.64 | 29.28 | Worse (Expensive) |
| ROE | 23.22% | 820.00% | Weak |
| Net Margin | 34.50% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 4.23 | 4.69 | Strong Liquidity |
| ROA | 18.42% | -17993.00% (disorted) | Strong |
CHGCY outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Chugai Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
70.23%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
145.30%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
116.15%
Industry Style: Defensive, Growth, Innovation
High Growth